Week of June 3, 2019 | Vol. 8, Issue 22
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
Viela Bio & Hansoh Pen Development Pact Potentially Worth $22 Million+
Hansoh will lead development and commercialization for the drug in China for NMOSD, a rare autoimmune disease that has no approved treatment.
People with NMOSD suffer attacks during which the immune system attacks the optic nerves, spinal cord and brain. These attacks can lead to paralysis and blindness. Current treatments such as immuno-suppressants and steroids are used off-label to treat or prevent attacks. None of them have been “studied in a rigorous fashion in NMOSD,” said Viela Bio Chief Medical Officer Jorn Drappa in a previous interview. The partnership comes three weeks after Viela  posted  positive pivotal data for inebilizumab in NMOSD. The study enrolled 231 patients with varying severities of disease, including patients with and without autoantibodies against a protein called aquaporin-4 (AQP4). AQP4 antibodies are a biomarker of NMOSD and are believed to trigger NMOSD attacks when they bind to the nervous system. Inebilizumab is given twice a year through an intravenous infusion that takes 90 minutes. After the six months, patients could sign up for an extension period during which they will receive additional doses of the drug every six months. 

 C ontinue Reading at Fierce Biotech .
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
14 transactions totaling $466 million
Supplies, Equipment & Services
12 transactions totaling $68 million
Healthcare IT & Managed Care
3 transactions totaling $26 million
Healthcare Facilities & Distributors
9 transactions totaling $35 million
Pharma & Biotech
18 transactions totaling $329 million
Supplies, Equipment & Services
20 transactions totaling $256 million
Healthcare IT & Managed Care
7 transactions totaling $330 million
Healthcare Facilities & Distributors
2 transactions totaling $3 million
Pharma & Biotech
19 transactions totaling $2,779 million
Supplies, Equipment & Services
4 transactions totaling $302 million
Healthcare IT & Managed Care
1 transaction
Healthcare Facilities & Distributors
1 transaction totaling $20 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
May 30, 2019 - Bio Pharma Dive
Vibalogics and Ampersand Capital Partners didn't disclose deal terms in a May 29 release, but the acquisition does bring 50 employees and a 27,000-square-foot manufacturing facility in Cuxhaven, Germany.

May 30, 2019 - Fierce Pharma
Cantor Fitzgerald analyst Louise Chen and her team made that comment in a Tuesday note to investors. Their reason? The Pfizer treatment's lower cost compared with its eventual rivals, for one thing. But, more important is a large population of patients with ATTR cardiomyopathy—1 million in the U.S. alone—that may be largely untapped now, but probably won't remain so for long.

May 28, 2019 - Fierce Biotech
Eli Lilly is paying $47.5 million upfront to  license  Centrexion Therapeutics’ phase 1 non-opioid pain drug. As the Big Pharma works on the program, Centrexion stands to net up to $575 million in development and regulatory milestones as well as another $375 million if the drug makes it to market.

May 28, 2019 - Fierce Biotech
Acquisitive Icon is at it again as it snaps up a majority stake in British site network company MeDiNova Research with an option to buy out the remaining shares penned into the deal.

May 28, 2019 - Fierce Pharma
Novartis’ promise of 25 potential blockbuster launches is steadily coming to fruition. On the same day the FDA approved gene therapy Zolgensma, the U.S. regulator also waved through breast cancer drug Piqray.
Recent Materials Providing Insight Into Healthcare Related Industries
May 2019